Medicinal plants of the genuses Salvia and Hypericum are sources of anticolon cancer compounds: Effects on PI3K/Akt and MAP kinases pathways

PharmaNutrition

Volumn 4, Issue 2, 2015, Pages 112-122

  Xavier, Cristina P R ^a   Pereira Wilson, Cristina ^a  

^a UNIVERSITY OF MINHO   (Portugal)

Author keywords

Colorectal cancer; Hypericum; MAPK; Nutraceuticals; PI3K Akt; Salvia

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; GUANINE NUCLEOTIDE BINDING PROTEIN; HYPERICUM ANDROSAEMUM EXTRACT; HYPERICUM PERFORATUM EXTRACT; LUTEOLIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PLANT EXTRACT; PROTEIN BAD; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; QUERCETIN; RAS PROTEIN; ROSMARINIC ACID; SALVIA FRUTICOSA EXTRACT; SALVIA MENTHAEFOLIA EXTRACT; SALVIA MILTIORRHIZA EXTRACT; SALVIA OFFICINALIS EXTRACT; SOMATOMEDIN RECEPTOR; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSOLIC ACID; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DRUG DETERMINATION; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HYPERICUM; HYPERICUM ANDROSAEMUM; HYPERICUM PERFORATUM; MEDICINAL PLANT; NONHUMAN; PHYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SALVIA; SALVIA FRUTICOSA; SALVIA OFFICINALIS; UPREGULATION;

EID: 84959297030     PISSN: None     EISSN: 22134344     Source Type: Journal    
DOI: 10.1016/j.phanu.2015.11.002     Document Type: Review

References (170)

1. Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 2009, 361(25):2449-2460.
2. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61(5):759-767.
3. Fearon E.R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 2011, 6:479-507.
4. Souglakos J. Genetic alterations in sporadic and hereditary colorectal cancer: implementations for screening and follow-up. Dig Dis. 2007, 25(1):9-19.
5. Segal N.H., Saltz L.B. Evolving treatment of advanced colon cancer. Annu. Rev. Med. 2009, 60:207-219.
6. Safarzadeh E., Sandoghchian Shotorbani S., Baradaran B. Herbal medicine as inducers of apoptosis in cancer treatment. Adv. Pharm. Bull. 2014, 4(Suppl 1):421-427.
7. Sultana S., Asif H.M., Nazar H.M., et al. Medicinal plants combating against cancer - a green anticancer approach. Asian Pac. J. Cancer Prev. 2014, 15(11):4385-4394.
8. Mondal S., Bandyopadhyay S., Ghosh M.K., et al. Natural products: promising resources for cancer drug discovery. Anticancer Agents Med. Chem. 2012, 12(1):49-75.
9. Ryan-Harshman M., Aldoori W. Diet and colorectal cancer: review of the evidence. Can. Fam. Phys. 2007, 53(11):1913-1920.
10. Romano M., Vitaglione P., Sellitto S., D'Argenio G. Nutraceuticals for protection and healing of gastrointestinal mucosa. Curr. Med. Chem. 2012, 19(1):109-117.
11. Schwingshackl L., Hoffmann G. Adherence to Mediterranean diet and risk of cancer: an updated systematic review and meta-analysis of observational studies. Cancer Med. 2015.
12. Surh Y.J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 2003, 3(10):768-780.
13. Yang C.S., Landau J.M. Effects of tea consumption on nutrition and health. J. Nutr. 2000, 130(10):2409-2412.
14. Yang C.S., Lambert J.D., Ju J., Lu G., Sang S. Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol. Appl. Pharmacol. 2007, 224(3):265-273.
15. Singh B.N., Shankar S., Srivastava R.K. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem. Pharmacol. 2011, 82(12):1807-1821.
16. Yang C.S., Ju J., Lu G., et al. Cancer prevention by tea and tea polyphenols. Asia Pac. J. Clin. Nutr. 2008, 17(Suppl. 1):245-248.
17. Yang C.S., Landau J.M., Huang M.T., Newmark H.L. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu. Rev. Nutr. 2001, 21:381-406.
18. Neergheen V.S., Bahorun T., Taylor E.W., Jen L.S., Aruoma O.I. Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology 2010, 278(2):229-241.
19. Loo G. Redox-sensitive mechanisms of phytochemical-mediated inhibition of cancer cell proliferation (review). J. Nutr. Biochem. 2003, 14(2):64-73.
20. Fruehauf J.P., Meyskens F.L. Reactive oxygen species: a breath of life or death?. Clin. Cancer Res. 2007, 13(3):789-794.
21. Gibellini L., Bianchini E., De Biasi S., et al. Natural compounds modulating mitochondrial functions. Evid. Based Compl. Alternat. Med. 2015, 2015:527209.
22. Martin-Cordero C., Leon-Gonzalez A.J., Calderon-Montano J.M., Burgos-Moron E., Lopez-Lazaro M. Pro-oxidant natural products as anticancer agents. Curr. Drug Targets 2012, 13(8):1006-1028.
23. Ramos S. Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol. Nutr. Food Res. 2008, 52(5):507-526.
24. Millimouno F.M., Dong J., Yang L., Li J., Li X. Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. Cancer Prev. Res. (Phila.) 2014, 7(11):1081-1107.
25. Yin S.Y., Wei W.C., Jian F.Y., Yang N.S. Therapeutic applications of herbal medicines for cancer patients. Evid. Based Compl. Alternat. Med. 2013, 2013:302426.
26. Qi F., Li A., Inagaki Y., et al. Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci. Trends 2010, 4(6):297-307.
27. Hosseini A., Ghorbani A. Cancer therapy with phytochemicals: evidence from clinical studies. Avicenna J. Phytomed. 2015, 5(2):84-97.
28. Furst R., Zundorf I. Evidence-based phytotherapy in Europe: Where do we stand?. Plant. Med. 2016, 2015.
29. Cravotto G., Boffa L., Genzini L., Garella D. Phytotherapeutics: an evaluation of the potential of 1000 plants. J. Clin. Pharm. Ther. 2010, 35(1):11-48.
30. McCubrey J.A., Steelman L.S., Abrams S.L., et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 2006, 46:249-279.
31. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 2007, 7(4):295-308.
32. Prior I.A., Lewis P.D., Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012, 72(10):2457-2467.
33. Barault L., Veyries N., Jooste V., et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int. J. Cancer 2008, 122:2255-2259.
34. Jiang Y., Kimchi E.T., Staveley-O'Carroll K.F., Cheng H., Ajani J.A. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer 2009, 115(16):3609-3617.
35. Oliveira C., Velho S., Moutinho C., et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 2007, 26(1):158-163.
36. Zhao L., Vogt P.K., Class I. PI3K in oncogenic cellular transformation. Oncogene 2008, 27(41):5486-5496.
37. Vara J.A.F., Casado E., de Castro J., et al. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 2004, 30(2):193-204.
38. Michl P., Downward J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z. Gastroenterol. 2005, 43(10):1133-1139.
39. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129(7):1261-1274.
40. Parsons D.W., Wang T.L., Samuels Y., et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005, 436(7052):792.
41. Velho S., Moutinho C., Cirnes L., et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?. BMC Cancer 2008, 8:255.
42. Wang J., Kuropatwinski K., Hauser J., et al. Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis. Mol. Cancer Ther. 2007, 6(3):1143-1150.
43. Guo X.N., Rajput A., Rose R., et al. Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. Cancer Res. 2007, 67(12):5851-5858.
44. Velho S., Oliveira C., Ferreira A., et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur. J. Cancer 2005, 41(11):1649-1654.
45. Oda K., Okada J., Timmerman L., et al. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 2008, 68(19):8127-8136.
46. Roy H.K., Olusola B.F., Clemens D.L., et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002, 23(1):201-205.
47. Khaleghpour K., Li Y., Banville D., Yu Z., Shen S.H. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 2004, 25(2):241-248.
48. Itoh N., Semba S., Ito M., et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002, 94(12):3127-3134.
49. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4(12):988-1004.
50. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 2008, 11(1-2):32-50.
51. Cheng J.Q., Lindsley C.W., Cheng G.Z., Yang H., Nicosia S.V. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005, 24(50):7482-7492.
52. Granville C.A., Memmott R.M., Gills J.J., Dennis P.A. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin. Cancer Res. 2006, 12(3 Pt 1):679-689.
53. Cuevas B.D., Abell A.N., Johnson G.L. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 2007, 26(22):3159-3171.
54. Fang J.Y., Richardson B.C. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005, 6(5):322-327.
55. Ikehara N., Semba S., Sakashita M., et al. BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. Int. J. Cancer 2005, 115(6):943-950.
56. Lee S.H., Lee J.W., Soung Y.H., et al. Colorectal tumors frequently express phosphorylated mitogen-activated protein kinase. APMIS 2004, 112(4-5):233-238.
57. Wee S., Jagani Z., Xiang K.X., et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 2009, 69(10):4286-4293.
58. Sarkar F.H., Li Y., Wang Z., Kong D. Cellular signaling perturbation by natural products. Cell Signal. 2009, 21(11):1541-1547.
59. Aggarwal B.B., Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 2006, 71(10):1397-1421.
60. Yang Y., Zhang Z., Li S., et al. Synergy effects of herb extracts: pharmacokinetics and pharmacodynamic basis. Fitoterapia 2014, 92:133-147.
61. Rajamanickam S., Agarwal R. Natural products and colon cancer: current status and future prospects. Drug Dev. Res. 2008, 69(7):460-471.
62. Slattery M.L., Lundgreen A., Wolff R.K. Dietary influence on MAPK-signaling pathways and risk of colon and rectal cancer. Nutr. Cancer 2013, 65(5):729-738.
63. Valentao P., Dias A., Ferreira M., et al. Variability in phenolic composition of Hypericum androsaemum. Nat. Prod. Res. 2003, 17(2):135-140.
64. Guedes A.P., Amorim L.R., Vicente A., Fernandes-Ferreira M. Variation of the essential oil content and composition in leaves from cultivated plants of Hypericum androsaemum L. Phytochem. Anal. 2004, 15(3):146-151.
65. Valentao P., Carvalho M., Fernandes E., et al. Protective activity of Hypericum androsaemum infusion against tert-butyl hydroperoxide-induced oxidative damage in isolated rat hepatocytes. J. Ethnopharmacol. 2004, 92(1):79-84.
66. Valentao P., Fernandes E., Carvalho F., et al. Antioxidant activity of Hypericum androsaemum infusion: scavenging activity against superoxide radical, hydroxyl radical and hypochlorous acid. Biol. Pharm. Bull. 2002, 25(10):1320-1323.
67. Valentao P., Carvalho M., Carvalho F., et al. Hypericum androsaemum infusion increases tert-butyl hydroperoxide-induced mice hepatotoxicity in vivo. J. Ethnopharmacol. 2004, 94(2-3):345-351.
68. Xavier C.P., Lima C.F., Fernandes-Ferreira M., Pereira-Wilson C. Hypericum androsaemum water extract inhibits proliferation in human colorectal cancer cells through effects on MAP kinases and PI3K/Akt pathway. Food Funct. 2012, 3(8):844-852.
69. Park H.J., Davis S.R., Liang H.Y., Rosenberg D.W., Bruno R.S. Chlorogenic acid differentially alters hepatic and small intestinal thiol redox status without protecting against azoxymethane-induced colon carcinogenesis in mice. Nutr. Cancer 2010, 62(3):362-370.
70. Xie Y.Y., Yuan D., Yang J.Y., Wang L.H., Wu C.F. Cytotoxic activity of flavonoids from the flowers of Chrysanthemum morifolium on human colon cancer Colon205 cells. J. Asian Nat. Prod. Res. 2009, 11(9):771-778.
71. Belkaid A., Currie J.C., Desgagnes J., Annabi B. The chemopreventive properties of chlorogenic acid reveal a potential new role for the microsomal glucose-6-phosphate translocase in brain tumor progression. Cancer Cell Int. 2006, 6:7.
72. Jin U.H., Lee J.Y., Kang S.K., et al. A phenolic compound, 5-caffeoylquinic acid (chlorogenic acid), is a new type and strong matrix metalloproteinase-9 inhibitor: isolation and identification from methanol extract of Euonymus alatus. Life Sci. 2005, 77(22):2760-2769.
73. Feng R., Lu Y., Bowman L.L., et al. Inhibition of activator protein-1, NF-kappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J. Biol. Chem. 2005, 280(30):27888-27895.
74. Barnes J., Anderson L.A., Phillipson J.D. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J. Pharm. Pharmacol. 2001, 53(5):583-600.
75. Russo E., Scicchitano F., Whalley B.J., et al. Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions. Phytother. Res. 2014, 28(5):643-655.
76. Roscetti G., Franzese O., Comandini A., Bonmassar E. Cytotoxic activity of Hypericum perforatum L. on K562 erythroleukemic cells: differential effects between methanolic extract and hypericin. Phytother. Res. 2004, 18(1):66-72.
77. Skalkos D., Stavropoulos N.E., Tsimaris I., et al. The lipophilic extract of Hypericum perforatum exerts significant cytotoxic activity against T24 and NBT-II urinary bladder tumor cells. Plant. Med. 2005, 71(11):1030-1035.
78. Martarelli D., Martarelli B., Pediconi D., et al. Hypericum perforatum methanolic extract inhibits growth of human prostatic carcinoma cell line orthotopically implanted in nude mice. Cancer Lett. 2004, 210(1):27-33.
79. Stavropoulos N.E., Kim A., Nseyo U.U., et al. Hypericum perforatum L. extract - novel photosensitizer against human bladder cancer cells. J. Photochem. Photobiol. B 2006, 84(1):64-69.
80. Karioti A., Bilia A.R. Hypericins as potential leads for new therapeutics. Int. J. Mol. Sci. 2010, 11(2):562-594.
81. Kitanov G.M. Hypericin and pseudohypericin in some Hypericum species. Biochem. Syst. Ecol. 2001, 29(2):171-178.
82. Mansky P.J., Straus S.E. St. John's Wort: more implications for cancer patients. J. Natl. Cancer Inst. 2002, 94(16):1187-1188.
83. Goey A.K., Mooiman K.D., Beijnen J.H., Schellens J.H., Meijerman I. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat. Rev. 2013, 39(7):773-783.
84. Haefeli W.E., Carls A. Drug interactions with phytotherapeutics in oncology. Expert Opin. Drug Metab. Toxicol. 2014, 10(3):359-377.
85. Zhou S., Chan E., Pan S.Q., Huang M., Lee E.J. Pharmacokinetic interactions of drugs with St John's wort. J. Psychopharmacol. 2004, 18(2):262-276.
86. Topcu G. Bioactive triterpenoids from Salvia species. J. Nat. Prod. 2006, 69(3):482-487.
87. Akaberi M., Mehri S., Iranshahi M. Multiple pro-apoptotic targets of abietane diterpenoids from Salvia species. Fitoterapia 2015, 100:118-132.
88. Fiore G., Nencini C., Cavallo F., et al. In vitro antiproliferative effect of six Salvia species on human tumor cell lines. Phytother. Res. 2006, 20(8):701-703.
89. Liu J., Shen H.M., Ong C.N. Salvia miltiorrhiza inhibits cell growth and induces apoptosis in human hepatoma HepG(2) cells. Cancer Lett. 2000, 153(1-2):85-93.
90. Su C.Y., Ming Q.L., Rahman K., Han T., Qin L.P. Salvia miltiorrhiza: traditional medicinal uses, chemistry, and pharmacology. Chin. J. Nat. Med. 2015, 13(3):163-182.
91. Sung B., Chung H.S., Kim M., et al. Cytotoxic effects of solvent-extracted active components of Bunge on human cancer cell lines. Exp. Ther. Med. 2015, 9(4):1421-1428.
92. Chen X., Guo J., Bao J., Lu J., Wang Y. The anticancer properties of Salvia miltiorrhiza Bunge (Danshen): a systematic review. Med. Res. Rev. 2014, 34(4):768-794.
93. Jafari E., Andalib S., Abed A., Rafieian-Kopaei M., Vaseghi G. Neuroprotective, antimicrobial, antioxidant, chemotherapeutic, and antidiabetic properties of Salvia reuterana: a mini review. Avicenna J. Phytomed. 2015, 5(1):10-16.
94. Kamatou G.P., Makunga N.P., Ramogola W.P., Viljoen A.M. South African Salvia species: a review of biological activities and phytochemistry. J. Ethnopharmacol. 2008, 119(3):664-672.
95. Zare Shahneh F., Valiyari S., Baradaran B., et al. Inhibitory and cytotoxic activities of Salvia officinalis L. Extract on human lymphoma and leukemia cells by induction of apoptosis. Adv. Pharm. Bull. 2013, 3(1):51-55.
96. Zare Shahneh F., Baradaran B., Orangi M., Zamani F. In vitro cytotoxic activity of four plants used in Persian traditional medicine. Adv. Pharm. Bull. 2013, 3(2):453-455.
97. Kontogianni V.G., Tomic G., Nikolic I., et al. Phytochemical profile of Rosmarinus officinalis and Salvia officinalis extracts and correlation to their antioxidant and anti-proliferative activity. Food Chem. 2013, 136(1):120-129.
98. Keshavarz M., Mostafaie A., Mansouri K., et al. In vitro and ex vivo antiangiogenic activity of Salvia officinalis. Phytother. Res. 2010, 24(10):1526-1531.
99. Kadioglu O., Efferth T. Pharmacogenomic characterization of cytotoxic compounds from Salvia officinalis in cancer cells. J. Nat. Prod. 2015, 78(4):762-775.
100. Abu-Dahab R., Afifi F., Kasabri V., Majdalawi L., Naffa R. Comparison of the antiproliferative activity of crude ethanol extracts of nine Salvia species grown in Jordan against breast cancer cell line models. Pharmacogn. Mag. 2012, 8(32):319-324.
101. Lima C.F., Valentao P.C., Andrade P.B., et al. Water and methanolic extracts of Salvia officinalis protect HepG2 cells from t-BHP induced oxidative damage. Chem. Biol. Interact. 2007, 167(2):107-115.
102. Xavier C.P., Lima C.F., Fernandes-Ferreira M., Pereira-Wilson C. Salvia fruticosa, Salvia officinalis, and rosmarinic acid induce apoptosis and inhibit proliferation of human colorectal cell lines: the role in MAPK/ERK pathway. Nutr. Cancer 2009, 61(4):564-571.
103. Ramos A.A., Pedro D., Collins A.R., Pereira-Wilson C. Protection by Salvia extracts against oxidative and alkylation damage to DNA in human HCT15 and CO115 cells. J. Toxicol. Environ. Health A 2012, 75(13-15):765-775.
104. Pedro D.F., Ramos A.A., Lima C.F., Baltazar F., Pereira-Wilson C. Colon cancer chemoprevention by sage tea drinking: decreased DNA damage and cell proliferation. Phytother. Res. 2015.
105. Riza E., Linos A., Petralias A., et al. The effect of Greek herbal tea consumption on thyroid cancer: a case-control study. Eur. J. Public Health 2015, 25(6):1001-1005.
106. Nichenametla S.N., Taruscio T.G., Barney D.L., Exon J.H. A review of the effects and mechanisms of polyphenolics in cancer. Crit. Rev. Food Sci. Nutr. 2006, 46(2):161-1683.
107. Khojasteh A., Mirjalili M.H., Hidalgo D., Corchete P., Palazon J. New trends in biotechnological production of rosmarinic acid. Biotechnol. Lett. 2014, 36(12):2393-2406.
108. Venkatachalam K., Gunasekaran S., Jesudoss V.A., Namasivayam N. The effect of rosmarinic acid on 1,2-dimethylhydrazine induced colon carcinogenesis. Exp. Toxicol. Pathol. 2013, 65(4):409-418.
109. Xu Y., Jiang Z., Ji G., Liu J. Inhibition of bone metastasis from breast carcinoma by rosmarinic acid. Plant. Med. 2010, 76(10):956-962.
110. Furtado R.A., de Araujo F.R., Resende F.A., Cunha W.R., Tavares D.C. Protective effect of rosmarinic acid on V79 cells evaluated by the micronucleus and comet assays. J. Appl. Toxicol. 2010, 30(3):254-259.
111. Furtado R.A., Oliveira B.R., Silva L.R., et al. Chemopreventive effects of rosmarinic acid on rat colon carcinogenesis. Eur. J. Cancer Prev. 2015, 24(2):106-112.
112. Li F.R., Fu Y.Y., Jiang D.H., et al. Reversal effect of rosmarinic acid on multidrug resistance in SGC7901/Adr cell. J. Asian Nat. Prod. Res. 2013, 15(3):276-285.
113. Scheckel K.A., Degner S.C., Romagnolo D.F. Rosmarinic acid antagonizes activator protein-1-dependent activation of cyclooxygenase-2 expression in human cancer and nonmalignant cell lines. J. Nutr. 2008, 138(11):2098-2105.
114. Lee J., Kim Y.S., Park D. Rosmarinic acid induces melanogenesis through protein kinase A activation signaling. Biochem. Pharmacol. 2007, 74(7):960-968.
115. Lima C.F., Fernandes-Ferreira M., Pereira-Wilson C. Phenolic compounds protect HepG2 cells from oxidative damage: relevance of glutathione levels. Life Sci. 2006, 79(21):2056-2068.
116. Bakota E.L., Winkler-Moser J.K., Berhow M.A., Eller F.J., Vaughn S.F. Antioxidant activity and sensory evaluation of a rosmarinic acid-enriched extract of Salvia officinalis. J. Food Sci. 2015, 80(4):C711-7.
117. Lamien-Meda A., Nell M., Lohwasser U., et al. Investigation of antioxidant and rosmarinic acid variation in the sage collection of the genebank in Gatersleben. J. Agric. Food Chem. 2010, 58(6):3813-3819.
118. Murakami A., Ashida H., Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008, 269(2):315-325.
119. Boots A.W., Haenen G.R., Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur. J. Pharmacol. 2008, 585(2-3):325-337.
120. Zhang H., Zhang M., Yu L., et al. Antitumor activities of quercetin and quercetin-5',8-disulfonate in human colon and breast cancer cell lines. Food Chem. Toxicol. 2012, 50(5):1589-1599.
121. Walker E.H., Pacold M.E., Perisic O., et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 2000, 6(4):909-919.
122. Granado-Serrano A.B., Angeles Martin M., Bravo L., Goya L., Ramos S. Time-course regulation of quercetin on cell survival/proliferation pathways in human hepatoma cells. Mol. Nutr. Food Res. 2008, 52(4):457-464.
123. Spencer J.P., Rice-Evans C., Williams R.J. Modulation of pro-survival Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and its in vivo metabolites underlie their action on neuronal viability. J. Biol. Chem. 2003, 278(37):34783-34793.
124. Lee K.W., Kang N.J., Heo Y.S., et al. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res. 2008, 68(3):946-955.
125. Gulati N., Laudet B., Zohrabian V.M., Murali R., Jhanwar-Uniyal M. The antiproliferative effect of Quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway. Anticancer Res. 2006, 26(2A):1177-1181.
126. Nguyen T.T., Tran E., Nguyen T.H., et al. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 2004, 25(5):647-659.
127. van Erk M.J., Roepman P., van der Lende T.R., et al. Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur. J. Nutr. 2005, 44(3):143-156.
128. Murtaza I., Marra G., Schlapbach R., et al. A preliminary investigation demonstrating the effect of quercetin on the expression of genes related to cell-cycle arrest, apoptosis and xenobiotic metabolism in human CO115 colon-adenocarcinoma cells using DNA microarray. Biotechnol. Appl. Biochem. 2006, 45(Pt 1):29-36.
129. Kim W.K., Bang M.H., Kim E.S., et al. Quercetin decreases the expression of ErbB2 and ErbB3 proteins in HT-29 human colon cancer cells. J. Nutr. Biochem. 2005, 16(3):155-162.
130. Wenzel U., Herzog A., Kuntz S., Daniel H. Protein expression profiling identifies molecular targets of quercetin as a major dietary flavonoid in human colon cancer cells. Proteomics 2004, 4(7):2160-2174.
131. Kim G.T., Lee S.H., Kim J.I., Kim Y.M. Quercetin regulates the sestrin 2-AMPK-p38 MAPK signaling pathway and induces apoptosis by increasing the generation of intracellular ROS in a p53-independent manner. Int. J. Mol. Med. 2014, 33(4):863-869.
132. Xavier C.P., Lima C.F., Preto A., et al. Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. Cancer Lett. 2009, 281(2):162-170.
133. Ranelletti F.O., Maggiano N., Serra F.G., et al. Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors. Int. J. Cancer 2000, 85(3):438-445.
134. Psahoulia F.H., Moumtzi S., Roberts M.L., et al. Quercetin mediates preferential degradation of oncogenic Ras and causes autophagy in Ha-RAS-transformed human colon cells. Carcinogenesis 2007, 28(5):1021-1031.
135. Xavier C.P., Lima C.F., Rohde M., Pereira-Wilson C. Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation. Cancer Chemother. Pharmacol. 2011, 68(6):1449-1457.
136. Volate S.R., Davenport D.M., Muga S.J., Wargovich M.J. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis 2005, 26(8):1450-1456.
137. Warren C.A., Paulhill K.J., Davidson L.A., et al. Quercetin may suppress rat aberrant crypt foci formation by suppressing inflammatory mediators that influence proliferation and apoptosis. J. Nutr. 2009, 139(1):101-105.
138. Ferry D.R., Smith A., Malkhandi J., et al. Phase I: clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res. 1996, 2(4):659-668.
139. Mulholland P.J., Ferry D.R., Anderson D., et al. Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Ann. Oncol. 2001, 12(2):245-248.
140. Ko W.G., Kang T.H., Lee S.J., Kim Y.C., Lee B.H. Effects of luteolin on the inhibition of proliferation and induction of apoptosis in human myeloid leukaemia cells. Phytother. Res. 2002, 16(3):295-298.
141. Lee L.T., Huang Y.T., Hwang J.J., et al. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res. 2002, 22(3):1615-1627.
142. Chang J., Hsu Y., Kuo P., et al. Increase of Bax/Bcl-XL ratio and arrest of cell cycle by luteolin in immortalized human hepatoma cell line. Life Sci. 2005, 76(16):1883-1893.
143. Lee W.J., Wu L.F., Chen W.K., Wang C.J., Tseng T.H. Inhibitory effect of luteolin on hepatocyte growth factor/scatter factor-induced HepG2 cell invasion involving both MAPK/ERKs and PI3K-Akt pathways. Chem. Biol. Interact. 2006, 160(2):123-133.
144. Lee H.J., Wang C.J., Kuo H.C., et al. Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK. Toxicol. Appl. Pharmacol. 2005, 203(2):124-131.
145. Pandurangan A.K., Esa N.M. Luteolin, a bioflavonoid inhibits colorectal cancer through modulation of multiple signaling pathways: a review. Asia. Pac. J. Cancer Prev. 2014, 15(14):5501-5508.
146. Kim J.A., Kim D.K., Kang O.H., et al. Inhibitory effect of luteolin on TNF-alpha-induced IL-8 production in human colon epithelial cells. Int. Immunopharmacol. 2005, 5(1):209-217.
147. Shi R.X., Ong C.N., Shen H.M. Luteolin sensitizes tumor necrosis factor-alpha-induced apoptosis in human tumor cells. Oncogene 2004, 23(46):7712-7721.
148. Lim do Y., Cho H.J., Kim J., et al. Luteolin decreases IGF-II production and downregulates insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells. BMC Gastroenterol. 2012, 12:9.
149. Shi R., Huang Q., Zhu X., et al. Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization. Mol. Cancer Ther. 2007, 6(4):1338-1347.
150. Ashokkumar P., Sudhandiran G. Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomed. Pharmacother. 2008, 62(9):590-597.
151. Manju V., Nalini N. Protective role of luteolin in 1,2-dimethylhydrazine induced experimental colon carcinogenesis. Cell Biochem. Funct. 2007, 25(2):189-194.
152. Wang L., Martins-Green M. Pomegranate and its components as alternative treatment for prostate cancer. Int. J. Mol. Sci. 2014, 15(9):14949-14966.
153. Ikeda Y., Murakami A., Ohigashi H. Ursolic acid: an anti- and pro-inflammatory triterpenoid. Mol. Nutr. Food Res. 2008, 52(1):26-42.
154. Chudzik M., Korzonek-Szlacheta I., Krol W. Triterpenes as potentially cytotoxic compounds. Molecules 2015, 20(1):1610-1625.
155. Shanmugam M.K., Dai X., Kumar A.P., et al. Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies. Biochem. Pharmacol. 2013, 85(11):1579-1587.
156. Zhang Y.X., Kong C.Z., Wang L.H., et al. Ursolic acid overcomes Bcl-2-mediated resistance to apoptosis in prostate cancer cells involving activation of JNK-induced Bcl-2 phosphorylation and degradation. J. Cell. Biochem. 2010, 109(4):764-773.
157. Zhang Y., Kong C., Zeng Y., et al. Ursolic acid induces PC-3 cell apoptosis via activation of JNK and inhibition of Akt pathways in vitro. Mol. Carcinog. 2010, 49(4):374-385.
158. Zhang Y.X., Kong C.Z., Wang H.Q., et al. Phosphorylation of Bcl-2 and activation of caspase-3 via the c-Jun N-terminal kinase pathway in ursolic acid-induced DU145 cells apoptosis. Biochimie 2009, 91(9):1173-1179.
159. Liu X.S., Jiang J. Induction of apoptosis and regulation of the MAPK pathway by ursolic acid in human leukemia K562 cells. Plant. Med. 2007, 73(11):1192-1194.
160. Yeh C.T., Wu C.H., Yen G.C. Ursolic acid, a naturally occurring triterpenoid, suppresses migration and invasion of human breast cancer cells by modulating c-Jun N-terminal kinase, Akt and mammalian target of rapamycin signaling. Mol. Nutr. Food Res. 2010, 54(9):1285-1295.
161. Achiwa Y., Hasegawa K., Udagawa Y. Regulation of the phosphatidylinositol 3-kinase-Akt and the mitogen-activated protein kinase pathways by ursolic acid in human endometrial cancer cells. Biosci. Biotechnol. Biochem. 2007, 71(1):31-37.
162. Wang X., Li L., Wang B., Xiang J. Effects of ursolic acid on the proliferation and apoptosis of human ovarian cancer cells. J. Huazhong Univ. Sci. Technol. Med. Sci. 2009, 29(6):761-764.
163. Shan J.Z., Xuan Y.Y., Zheng S., Dong Q., Zhang S.Z. Ursolic acid inhibits proliferation and induces apoptosis of HT-29 colon cancer cells by inhibiting the EGFR/MAPK pathway. J. Zhejiang Univ. Sci. B 2009, 10(9):668-674.
164. Wang J., Liu L., Qiu H., et al. Ursolic acid simultaneously targets multiple signaling pathways to suppress proliferation and induce apoptosis in colon cancer cells. PLoS One 2013, 8(5):e3872.
165. Lin J., Chen Y., Wei L., et al. Ursolic acid inhibits colorectal cancer angiogenesis through suppression of multiple signaling pathways. Int. J. Oncol. 2013, 43(5):1666-1674.
166. Lin J., Chen Y., Wei L., et al. Ursolic acid promotes colorectal cancer cell apoptosis and inhibits cell proliferation via modulation of multiple signaling pathways. Int. J. Oncol. 2013, 43(4):1235-1243.
167. Xavier C.P., Lima C.F., Pedro D.F., et al. Ursolic acid induces cell death and modulates autophagy through JNK pathway in apoptosis-resistant colorectal cancer cells. J. Nutr. Biochem. 2013, 24(4):706-712.
168. Prasad S., Yadav V.R., Sung B., et al. Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. Clin. Cancer Res. 2012, 18(18):4942-4953.
169. Li Y., Xing D., Chen Q., Chen W.R. Enhancement of chemotherapeutic agent-induced apoptosis by inhibition of NF-kappaB using ursolic acid. Int. J. Cancer 2010, 127(2):462-473.
170. Zhu Z., Qian Z., Yan Z., et al. A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors. Int. J. Nanomed. 2013, 8:129-136.